76240-49-8

Basic information

• Product Name: 6-broMophthalazine-1,4-diol
• Synonyms: 6-broMophthalazine-1,4-diol;6-Bromo-2,3-dihydrophthalazine-1,4-dione;1(2H)-PHTHALAZINE, 7-BROMO-4-HYDROXY
• CAS NO: 76240-49-8
• Molecular Formula: C₈H₅BrN₂O₂
• Molecular Weight: 241.0415
• Mol File: 76240-49-8.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• Density: 1.752±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 9.87±0.20(Predicted)
• CAS DataBase Reference: 6-broMophthalazine-1,4-diol(CAS DataBase Reference)
• NIST Chemistry Reference: 6-broMophthalazine-1,4-diol(76240-49-8)
• EPA Substance Registry System: 6-broMophthalazine-1,4-diol(76240-49-8)

Safety Data

• Hazardous Substances Data: 76240-49-8(Hazardous Substances Data)

Usage

General Description

6-Bromophthalazine-1,4-diol is a chemical compound with the molecular formula C8H5BrN2O2. This chemical belongs to the class of organic compounds known as phthalazines, which are polycyclic aromatic compounds containing a phenazine moiety, a large planar seven-membered ring fused to a benzene ring. In 6-Bromophthalazine-1,4-diol, bromine is attached to the six-membered benzene ring and hydroxy groups are attached at positions 1 and 4 of the seven-membered ring. 6-broMophthalazine-1,4-diol does not have any significant commercial uses and is mostly utilized in laboratory research.

Upstream product

• 86-90-8 4-bromophthalic anhydride 

Downstream Products

• 939052-90-1 6-bromo-2,3-bis(4-methoxybenzyl)-2,3-dihydrophthalazine-1,4-dione 
• 1028338-57-9 7-bromo-4-chloro-2H-phthalazin-1-one 
• 1028338-59-1 6-bromo-4-chlorophthalazin-1(2H)-one 
• 240400-95-7 6-bromo-1,4-dichloro-phthalazine 
• 1366408-06-1 8-bromo-13-(4-methoxyphenyl)-3,4-dihydro-1H-indazolo[2,1-b]phthalazine-1,6,11(2H,13H)-trione 
• 1366408-04-9 8-bromo-13-phenyl-3,4-dihydro-1H-indazolo[2,1-b]phthalazine-1,6,11(2H,13H)-trione 
• 1366408-05-0 8-bromo-13-(4-chlorophenyl)-3,4-dihydro-1H-indazolo[2,1-b]phthalazine-1,6,11(2H,13H)-trione 
• 1366408-07-2 8-bromo-13-(3,4-dimethylphenyl)-3,4-dihydro-1H-indazolo[2,1-b]phthalazine-1,6,11(2H,13H)-trione 

Relevant articles and documents

N -Chlorinative Ring Contraction of 1,4-Dimethoxyphthalazines via a Bicyclization/Ring-Opening Mechanism

An unprecedented N -chlorinative ring contraction of 1,2-diazines was discovered and investigated with an electrophilic chlorinating reagent, trichloroisocyanuric acid (TCICA). Through optimization and mechanistic analysis, the assisting role of n -Bu 4NCl as an exogenous nucleophile was identified, and the optimized reaction conditions were applied to a range of 1,4-dimethoxyphthalazine derivatives. Also, an improvement of overall efficiency was demonstrated by the use of a labile O -silyl group. A bicyclization/ring-opening mechanism, inspired by the Favorskii rearrangement, was proposed and supported by the DFT calculations. Furthermore, the efforts on scope expansion as well as the evaluation of other electrophilic promoters revealed that the newly developed ring contraction reactivity is a unique characteristic of 1,4-dimethoxyphthalazine scaffold and TCICA.

MTA-Cooperative PRMT5 Inhibitors

The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

Cell-Active Small Molecule Inhibitors of the DNA-Damage Repair Enzyme Poly(ADP-ribose) Glycohydrolase (PARG): Discovery and Optimization of Orally Bioavailable Quinazolinedione Sulfonamides

DNA damage repair enzymes are promising targets in the development of new therapeutic agents for a wide range of cancers and potentially other diseases. The enzyme poly(ADP-ribose) glycohydrolase (PARG) plays a pivotal role in the regulation of DNA repair mechanisms; however, the lack of potent drug-like inhibitors for use in cellular and in vivo models has limited the investigation of its potential as a novel therapeutic target. Using the crystal structure of human PARG in complex with the weakly active and cytotoxic anthraquinone 8a, novel quinazolinedione sulfonamides PARG inhibitors have been identified by means of structure-based virtual screening and library design. 1-Oxetan-3-ylmethyl derivatives 33d and 35d were selected for preliminary investigations in vivo. X-ray crystal structures help rationalize the observed structure-activity relationships of these novel inhibitors.